Journal: Journal of Cancer Research and Clinical Oncology

Article Title: New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

doi: 10.1007/s00432-020-03144-7

Figure Lengend Snippet: Optimization and specificity of CELx HSF Test in primary tumor cells. Dose–response curves of NRG1b ( a ) and EGF ( b ) stimulation of CELx signals in C899 patient primary breast tumor cells that were classified as HER2-negative based on histopathological analysis. c Dose–response curve of pertuzumab showing its specific inhibitory effect on NRG1b-driven CELx signal

Article Snippet: The 10 µg/mL 2C4 is a conservative concentration that is also consistent with therapeutic levels of pertuzumab in patient sera (Perjeta (pertuzumab) [package insert] Genentech, Inc. South San Francisco, CA 2012; Quartino AL 2017).

Techniques:

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

doi: 10.1007/s00432-020-03144-7

Figure Lengend Snippet: Percent inhibition of NRG1b CELx signal for HER2+ cell lines versus HER2−/HSFs+ patient samples . Inhibition of NRG1-driven HER2 signaling by pertuzumab (10 mg/mL) or trastuzumab (10 mg/mL) alone or in combination in the CELx test. Percentages shown represent the average of four HER2+ HSFs+ cell lines (SKBR3, EFM192A, HCC1569, and ZR75-30) or 5 HER2−/HSFs+ primary tumor samples (C978, C133, C264, C309, and C371), performed with 2 technical replicates per biological sample

Article Snippet: The 10 µg/mL 2C4 is a conservative concentration that is also consistent with therapeutic levels of pertuzumab in patient sera (Perjeta (pertuzumab) [package insert] Genentech, Inc. South San Francisco, CA 2012; Quartino AL 2017).

Techniques: Inhibition

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

doi: 10.1007/s00432-020-03144-7

Figure Lengend Snippet: Comparison of inhibition of NRG1-driven HER2 signaling by HER2 targeted therapeutics. Pertuzumab (10 μg/mL), lapatinib (200 nM), afatinib (120 nM), or neratinib (500 nM) inhibition of NRG1-driven HER2 signaling is shown as the average of 9 HER2+ cell lines (SKBR3, EFM192A, ZR75-30, HCC202, HCC1954, HCC1569, MDA-MB361, BT474, AU565) or 7 HER2−/HER2s+ primary tumors (R69, R20, R160, R82, R95, R25, R71) performed with 2 technical replicates per biological sample. Single dose concentrations were selected for relative comparator purposes only where a maximal amount of the signaling was inhibited in at least one of the samples. Variances from 100% inhibition likely arise from ligand generated signaling that was not directly related to HER activity or where a sample had some level of drug paradoxical response (Claus et al. )

Article Snippet: The 10 µg/mL 2C4 is a conservative concentration that is also consistent with therapeutic levels of pertuzumab in patient sera (Perjeta (pertuzumab) [package insert] Genentech, Inc. South San Francisco, CA 2012; Quartino AL 2017).

Techniques: Inhibition, Generated, Activity Assay